Heart Failure Clinical Trial
Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Summary
The researchers hypothesize that the addition of nesiritide to standard therapy will prevent worsening of renal function in patients admitted to the hospital with decompensated heart failure and renal dysfunction relative to standard therapy alone.
Eligibility Criteria
Inclusion Criteria:
Decompensated heart failure hospitalization with at least 1 symptom and 1 sign of elevated filling pressures
Admission estimated creatinine clearance =< 50 cc/min.
Exclusion Criteria:
Systolic blood pressure < 85 mm Hg
Cardiogenic shock
Volume depletion
Myocardial infarction, unstable angina within last 30 days
Significant valvular stenosis, hypertrophic/restrictive cardiomyopathy, or constrictive pericarditis
Chronic hemodialysis
Anticipated major procedure during hospitalization i.e. left heart catheterization, surgery, or transplantation
Enrolled in another research protocol within last 30 days.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Boston Massachusetts, 02115, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.